<- Go Home
2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Market Cap
$266.1M
Volume
610.6K
Cash and Equivalents
$92.4M
EBITDA
-$52.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$13.2M
Profit Margin
27.37%
52 Week High
$5.30
52 Week Low
$2.29
Dividend
N/A
Price / Book Value
1.23
Price / Earnings
-63.66
Price / Tangible Book Value
1.26
Enterprise Value
$332.5M
Enterprise Value / EBITDA
-7.20
Operating Income
-$59.4M
Return on Equity
1.94%
Return on Assets
-7.49
Cash and Short Term Investments
$170.4M
Debt
$239.8M
Equity
$214.0M
Revenue
$48.4M
Unlevered FCF
-$40.4M
Sector
Biotechnology
Category
N/A